TrialDiabetologia2021

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.

Bart Keymeulen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.